Journal Information
Review Article
Full text access
Pre-proof, online 31 July 2025
Biological therapy in COPD management: current evidence, challenges and opportunities
Visits
2
Dave Singh1,2,
, Antonio Menéndez Lobo3, Andrew Higham1, Bernardino Alcázar Navarrete4,5
1 Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK, United Kingdom
2 Medicines Evaluation Unit, The Langley Building, Southmoor Road, Manchester, UK, United Kingdom
3 Respiratory Department. Fundación Hospital de Jové, Gijón, Spain
4 Respiratory Department. Hospital Universitario Virgen de las Nieves. Ibs- Granada, Granada, Spain
5 Medicine Department. Universidad de Granada, Granada, Spain
This item has received
Article information
Abstract

The goals of COPD treatment are to improve symptoms and decrease future risks such as exacerbations, lung function decline and mortality. Despite receiving maximal inhaled treatment, many COPD patients continue to exacerbate. This highlights the need for novel therapeutic approaches. There is now positive clinical trial data supporting the use of monoclonal antibody treatments in COPD. There remain challenges to define responder populations for each monoclonal antibody class on the basis of clinical characteristics and biomarkers. There are considerable future opportunities, including the targeting of disease activity with monoclonal antibodies at earlier stages in the natural history of COPD in order to slow the rate of disease progression. Using monoclonal antibodies during an exacerbation as a targeted treatment also hold potential. Monoclonal antibody treatments have the potential to change the landscape of COPD management.

Full text is only available in PDF
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?